Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 5/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15529385 | 1.00 | ALDH1A1 (0.65) | ALDH1A1CYP2C19POLBTDP1APEX1 | |
| SCHEMBL2033299 | 1.00 | ALDH1A1 (0.65) | ALDH1A1CYP2C19POLBTDP1APEX1 | |
| SCHEMBL7232865 | 1.00 | ALDH1A1 (0.65) | ALDH1A1CYP2C19POLBTDP1APEX1 | |
| SCHEMBL311527 | 1.00 | ALDH1A1 (0.65) | ALDH1A1CYP2C19POLBTDP1APEX1 | |
| Hydrochloric Acid SCHEMBL26613189 | 0.98 | ALDH1A1 (0.63) | ALDH1A1CYP2C19POLBTDP1APEX1 | |
| Hydrochloric Acid SCHEMBL26613207 | 0.98 | ALDH1A1 (0.63) | ALDH1A1CYP2C19POLBTDP1APEX1 | |
| Hydrochloric Acid SCHEMBL19668549 | 0.98 | ALDH1A1 (0.63) | ALDH1A1CYP2C19POLBTDP1APEX1 | |
| Hydrochloric Acid SCHEMBL19668550 | 0.98 | ALDH1A1 (0.63) | ALDH1A1CYP2C19POLBTDP1APEX1 | |
| SCHEMBL24062391 | 0.83 | POLB (0.70) | ALDH1A1POLBTDP1APEX1SMN1; SMN2 | |
| SCHEMBL20346210 | 0.83 | POLB (0.70) | ALDH1A1POLBTDP1APEX1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024150597-A1 | THERMOSETTING RESIN COMPOSITION, CURED FILM, SUBSTRATE, AND ELECTRONIC COMPONENT | JNC株式会社 | 2024-07-18 | — | — | WO | disclosed |
| US-9173869-B2 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | CURIS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130303547-A1 | HCV Protease Inhibitors and Uses Thereof | ABBVIE INC (US) | 2013-11-14 | — | — | US | disclosed |
| US-8497275-B2 | HCV protease inhibitors and uses thereof | ABBVIE INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20110077256-A1 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO | GUICHERIT OIVIN M | 2011-03-31 | — | — | US | disclosed |
| US-20100029686-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-02-04 | — | — | US | disclosed |
| US-7595327-B2 | Exo-N-Hydroxy-3-[methyl({4-[(2-methylquinolin-4-yl) methoxy]phenyl}sulfonyl)amino]bicyclo[2.2.1]heptane-2-carboxamide; rheumatoid arthritis (RA), juvenile RA, psoriatic arthritis, ankylosing spondylitis, psoriasis, osteoarthritis, tumor metastasis, sepsis, AIDS, ulcerative colitis, multiple sclerosis | WYETH (US) | 2009-09-29 | — | — | US | disclosed |
| WO-2008074035-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20070021493-A1 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | CURIS, INC. (US) | 2007-01-25 | — | — | US | disclosed |
| US-20060211730-A1 | Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase | WYETH (US) | 2006-09-21 | — | — | US | disclosed |
| US-20050080138-A1 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | CURIS, INC. (US) | 2005-04-14 | — | — | US | disclosed |
| EP-1516876-A1 | Mediators of hedgehog signalling pathways, compositions and uses related thereto | Curis, Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| EP-1216234-B1 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO | CURIS INC (US) | 2004-12-29 | — | — | EP | disclosed |
| US-6545005-B1 | Quinazolone derivatives | CURTIS, INC. | 2003-04-08 | — | — | US | disclosed |
| WO-2001019800-A9 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO | CURIS INC (US) | 2002-10-03 | — | — | WO | disclosed |
| EP-1216234-A2 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO | Curis, Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001019800-A2 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO | CURIS, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211730-A1 | Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase | SI, MMP12, TNF | ALDH1A1 2176/4885CYP2C19 2316/4885POLB 1265/4885 |
| US-20130303547-A1 | HCV Protease Inhibitors and Uses Thereof | SERPINB1, PEPD, PREP | ALDH1A1 1056/4885CYP2C19 511/4885POLB 2001/4885 |
| US-20070021493-A1 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | SHH, SMO, GLI1 | ALDH1A1 4299/4885CYP2C19 4885/4885POLB 4468/4885 |
| US-20100029686-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | SERPINB1, PEPD, PREP | ALDH1A1 1056/4885CYP2C19 511/4885POLB 2001/4885 |
| US-20050080138-A1 | Mediators of hedgehog signaling pathways, compositions and uses related thereto | SHH, SMO, GLI1 | ALDH1A1 4299/4885CYP2C19 4885/4885POLB 4468/4885 |
| US-20110077256-A1 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO | SHH, SMO, GLI1 | ALDH1A1 4299/4885CYP2C19 4885/4885POLB 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.